Stage IVA EGFR-mutant lung adenocarcinoma: response to triple targeted therapy and surgery

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial EGFR exon 19 deletion; acquired BRAF V600E mutation in progressive lesion while EGFR exon 19 deletion persisted

Metastatic Site: pleura, pulmonary metastases; mediastinal and left…

As of May 2025, she continued osimertinib, dabrafenib, and trametinib after segmentectomy/lymphadenectomy, with 1% viable residual tumor in resected lung lesions, complete nodal pathologic response, and no disease progression.

PubMed CentralRead more →

Stage IVB ROS1-rearranged lung adenocarcinoma with bilateral ocular metastases: durable response to entrectinib

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: EZR-ROS1 fusion with mutation frequency 42.99%; TTF-1-positive in lung and left-eye tumor tissue

Metastatic Site: bilateral uveal/ocular metastases; bronchial lymph…

After about 3 years on entrectinib, systemic disease remained well controlled with partial remission, both eyes had best corrected visual acuity of 20/20, and no treatment-related discomfort or adverse events were reported.

PubMed CentralRead more →

EGFR L858R lung adenocarcinoma presenting as rectal and peritoneal metastases

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Rectal/peritoneal tumors supported lung origin. Key result: EGFR L858R with TP53 mutations; no other actionable lung alteration reported.

Metastatic Site: rectum; peritoneum; omentum; mesentery; colonic wall

After transverse colostomy and confirmation of EGFR L858R-mutant lung adenocarcinoma metastasis, aumolertinib led to clinical stabilization; palliative radiotherapy was later given to the rectal lesion, but long-term follow-up was not yet available.

PubMed CentralRead more →

ALK-fusion lung adenocarcinoma with pleural progression: alectinib toxicity and switch to lorlatinib

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: EML4::ALK fusion positive

Metastatic Site: pleura

After pleural progression, disease was stable on ALK-targeted therapy; lorlatinib was tolerated after alectinib-related hemolysis and bradycardia resolved.

PubMed CentralRead more →

Stage IIIA lung adenocarcinoma: complete metabolic remission after chemoradiotherapy, complicated by radiation esophagitis

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: No molecular biomarkers reported

The primary lung lesion achieved complete metabolic remission after concurrent chemoradiotherapy, and radiation esophagitis/stricture improved with conservative management until swallowing returned to a normal diet by 16 months.

PubMed CentralRead more →

Stage IV lung adenocarcinoma with paraneoplastic nephrotic syndrome during pembrolizumab therapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1 tumor proportion score >50% by Roche SP263 assay; KRAS exon 3 mutation; NGS/FISH did not identify targets for first-line targeted therapy

Metastatic Site: brain, bone

Pembrolizumab produced partial response and improved nephrotic-syndrome parameters, but bone metastases progressed in September 2022 and the right upper-lobe target lesion progressed 2 months later, leading to carboplatin plus pemetrexed.

PubMed CentralRead more →

KRAS G12C lung adenocarcinoma with hypertrophic pulmonary osteoarthropathy: no recurrence after lobectomy

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: KRAS detected; PD-L1 <1%

At 1-year follow-up, there was no evidence of recurrence; pain, edema, grip strength, and periosteal thickening related to hypertrophic pulmonary osteoarthropathy improved after surgery.

PubMed CentralRead more →

Stage IVA right lung squamous cell carcinoma: partial response complicated by camrelizumab-related pneumonitis and pulmonary bullae

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: Squamous lung cancer marker profile: P40/CK5/6 positive, TTF-1/Napsin A negative. CEA/CYFRA tumor markers were elevated. PD-L1 not reported.

Metastatic Site: suspected pleural involvement / right pleural effusion

The cancer had a partial response to albumin-bound paclitaxel, carboplatin, and camrelizumab; camrelizumab was stopped after suspected immune-related pneumonitis, pulmonary embolism, and reversible pulmonary bullae, which improved after methylprednisolone was resumed.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Emily's Patient Story

Patient Info: Emily, Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Right lung; right 8th rib; sacrum; pancreas; brain

Emily had Stage IV EGFR-mutated lung cancer treated with daily targeted therapy, 4 rounds of chemotherapy, and later radiation. As of September 2025, she felt well and described being almost/basically in remission, but her cancer remained treatable rather than curable and she continued daily targeted therapy.

The Patient StoryRead more →

Stage IV HER2-Positive Non-Small Cell Lung Cancer: Lauren's Patient Story

Patient Info: Lauren, Female, Under 40 | Stage IV

Biomarkers: HER2 mutation

Metastatic Site: Bones/ribs/shoulder; liver

As of September 2025, after about 4 months of targeted therapy, Lauren reported better quality of life, resolved bone pain, improved liver pain, improved liver enzymes, and manageable infusion-week side effects.

The Patient StoryRead more →

Stage IV ALK Lung Cancer: Shauna's Patient Story

Patient Info: Shauna, Female, 50s | Stage IV

Biomarkers: ALK-positive

Metastatic Site: Both lungs

Shauna had Stage IV ALK-positive lung cancer involving both lungs. She was stable for about 5 years on her first TKI, had radiation for limited lung growth, and later switched to a newer TKI with stable scans. She explicitly said she had never had no evidence of disease, so the record should not be labeled NED.

The Patient StoryRead more →

Stage III Lung Cancer Treatment Complicated by Adult T-Cell Leukemia/Lymphoma

Patient Info: Anonymized, male, 70+ | Stage III

The lung cancer had a partial response after chemoradiotherapy, and no lung-cancer progression was observed after durvalumab was stopped during subsequent follow-up.

PubMed CentralRead more →

Stage IIIA KRAS p.G12V lung adenocarcinoma: pathologic complete response after chemoimmunotherapy and surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: KRAS p.G12V mutation; PD-L1 0% tumor-cell staining; <1% tumor-associated inflammatory-cell staining; no EGFR, ALK, or ROS1 driver mutation reported

Pathology after lobectomy showed a pathologic complete response, and surveillance imaging 12 months later showed no evidence of disease recurrence.

PubMed CentralRead more →

Stage IV lung adenocarcinoma with brain and right shoulder-joint metastases: durable pain relief after SBRT

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: brain; right shoulder joint

Right shoulder pain resolved within 1 week of SBRT, PET/CT at 6 months showed no FDG uptake in the joint, and there was no right shoulder pain recurrence at the final examination 9 years and 3 months after SBRT.

PubMed CentralRead more →

Stage IIIA lung adenocarcinoma complicated by severe atezolizumab-induced liver toxicity

Patient Info: Anonymized, Male, 60s | Stage III

Biomarkers: PD-L1 49%; case text describes triple-negative status without expanding the specific markers

The patient was discharged clinically stable but with guarded prognosis after atezolizumab-induced vanishing bile duct syndrome, requiring prednisone, mycophenolate mofetil, ursodeoxycholic acid, prophylaxis, and close oncology/internal medicine follow-up.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Steven's Patient Story

Patient Info: Steven Huff, Male, Under 40 | Stage IV

Biomarkers: ALK-positive

Metastatic Site: Lungs; liver; spine; sacrum; chest lymph nodes;…

Steven had Stage IV ALK-positive NSCLC and responded well to twice-daily oral targeted therapy, with several years of stable scans and a return to teaching and family life. As of September 2025, he remained on active treatment rather than being cancer-free.

The Patient StoryRead more →

Lung adenocarcinoma surgery complicated by postoperative chest wall hernia

Patient Info: Anonymized, Male, 70+

He completed VATS left lower lobectomy for lung adenocarcinoma and later mesh repair of a postoperative chest wall hernia; at 6 months after hernia repair, the hernia had not recurred.

PubMed CentralRead more →

Extensive-stage small-cell lung cancer with immune-related diabetes and stable disease at 2 years

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Tumor PD-L1 not reported. Immune-related diabetes showed very low C-peptide and negative diabetes autoantibodies; thyroiditis also occurred.

Metastatic Site: pancreas; pleura/pleural effusion; mediastinal lymph…

Two years after the SCLC diagnosis, she was alive with stable oncologic disease after later brain metastases were treated with whole-brain radiotherapy, and she remained insulin-dependent.

PubMed CentralRead more →

Localized lung adenocarcinoma: lobectomy followed by air-leak repair

Patient Info: Anonymized, Male, 60s

After lobectomy and a second thoracoscopic repair for persistent postoperative air leak, the air leak resolved by postoperative day 3 and had not recurred at 2-month follow-up.

PubMed CentralRead more →

Small-cell lung cancer with anti-NMDAR encephalitis: neurologic recovery and cancer care ongoing

Patient Info: Anonymized, Male, 70+

Biomarkers: Anti-NMDAR antibodies positive in cerebrospinal fluid; tumor molecular markers not reported

He recovered without significant neurologic sequelae and had no recurrence of neuropsychiatric symptoms; SCLC treatment with carboplatin and paclitaxel began after discharge, and cancer remission status was not documented.

PubMed CentralRead more →

Metastatic lung squamous cell carcinoma with T3 vertebral fracture responding to treatment

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: bone (T3 vertebra)

Follow-up imaging at 16 weeks showed sclerosis of the T3 lesion, the patient remained neurologically intact, and brace use could be discontinued.

PubMed CentralRead more →

Stage IV ALK Lung Adenocarcinoma: Allison's Patient Story

Patient Info: Allison, Female, 40s | Stage IV

Biomarkers: ALK-positive fusion; later ALK resistance mutations reported

Metastatic Site: Bone (spine, femur, ribs, shoulder); brain

Allison was living with Stage IV ALK-positive lung cancer and had a strong response to targeted therapy: brain lesions cleared, most PET activity resolved, and the primary tumor shrank to about 1.5 cm. As of August 2025, she remained on second-line targeted therapy.

The Patient StoryRead more →

Metastatic lung adenocarcinoma with brain and iliac bone response to chemoimmunotherapy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1-negative; no EGFR, ALK, ROS1, RET, KRAS, BRAF, MET, HER2, or NTRK alteration detected; TP53 mutation found.

Metastatic Site: left iliac bone, brain

Brain metastases achieved complete remission without cranial irradiation, and lung, bone, and brain lesions remained stable at last follow-up, with PFS of 35 months and OS exceeding 40 months.

PubMed CentralRead more →

KRAS Lung Cancer: Wyatt's Patient Story

Patient Info: Wyatt, Male

Biomarkers: KRAS mutation mentioned indirectly; exact variant not stated in available source text

Wyatt was living with lung cancer on ongoing chemotherapy and immunotherapy, with multiple prior lines of treatment and significant side effects. As of August 2025, he had tried to access clinical trials but had not enrolled.

The Patient StoryRead more →